| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaeb7340c08788bafb7d7d2493cb84bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c97fa5a79ef61fbc13233b8e9e3b258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b265726490e49762361587e82c9f84b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1998-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe3dca370eccc91c479bf14bcaf279b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29b68e7183c9b3b194aef67e0c50c77a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d41d71fd0744b565510ab8e04096ef7 |
| publicationDate |
1998-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9850062-A1 |
| titleOfInvention |
Compositions and methods of therapy for igf-i-responsive conditions |
| abstract |
Compositions and methods useful in therapy for IGF-I-responsive conditions in a mammal are provided. The method comprises concurrent therapy with both IGF-I or a variant thereof and at least one GAG to promote a desired therapeutic response with respect to a particular IGF-I- responsive condition. Concurrent therapy is achieved by admininstering to a mammal a single pharmaceutical composition containing both IGF-I (or a variant thereof) and at least one GAG according to a dosing regimen. Alternatively, IGF-I or a variant thereof and at least one GAG can be administered as two separate pharmaceutical compositions. A pharmaceutical composition comprising IGF-I or a variant thereof and at least one GAG for use in the IGF-I and GAG therapy is also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1797869-A3 |
| priorityDate |
1997-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |